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 Abstract. The present study was aimed at identifying the
molecular profile characteristic of the healthy human
gastric mucosa. Ex vivo HR-MAS magnetic resonance
spectroscopy performed at 9.4 Tesla (400.13 MHz for 1H) on
gastric specimens collected during endoscopy, permits the
identification of more than forty species giving a detailed
picture of the biochemical pattern of the gastric tissues. These
preliminary data will be used for a comparison with gastric
preneoplastic and neoplastic situations. Moreover, the full
knowledge of the biochemical pattern of the healthy gastric
tissues is the necessary presupposition for the application of
magnetic resonance spectroscopy directly in vivo.
Introduction
The neoplasms of the human gastrointestinal tract are an
important public health problem due to their high incidence
(1) and the high rates of recurrence and metastasis after
resection, the outcome of treatment being highly dependent
on correct and early diagnosis. The detection of early lesions,
without lymph node involvement or distant metastases, will
result in a reduction of mortality (2). Thus, achieving a better
understanding of the molecular features of gastric and colo-
rectal tumors and the development of reliable methods for
early detection is highly desiderable.
In vivo magnetic resonance spectroscopy (MRS) is a
molecular investigation method well suited for attempting to
correlate the biochemical composition of tissues with their
diseases with particular regard to neoplasms (3). The clinical
impact of MRS in medicine has been widely reviewed by
Smith and Steward (4) and is currently showing promise as
method to complement routine diagnostic tools such as endo-
scopy and histopathology. It provides biochemical information,
and is thus in a position to detect early, premorphological
molecular changes in tissue. MRS of cultured cells and of
biopsy specimens from humans have demonstrated great
sensitivity to the onset of malignancy by comparing human
healthy and neoplastic tissues (5). Whereas organs, such as
the brain (6-10), prostate (11,12) and breast (13-15) have
been widely studied, and MRS is used routinely in clinical
medicine to analyse them, MRS in the evaluation of neoplasms
of human gastrointestinal mucosa is in its infancy.
Recently, an ex vivo 1H MRS study of human gastric
carcinomas was reported (16). Notwithstanding this work
was aimed to assess the clinical importance and usefulness of
the MRS in the evaluation of human gastric carcinoma, we
believe that a better precision in the metabolite assignments
is desiderable.
In vivo MRS can be used when the molecular markers of
the tissues are well established by means of a detailed bio-
chemical picture. This is performed, in a first stage, by the
spectroscopic analysis on the extracts obtained from the
tissues (in vitro MRS) or directly on tissue specimens (ex vivo
MRS). High resolution magic angle spinning (HR-MAS)
ex vivo MRS is a powerful analytical tool for human tissues
potentially bridging the divide between in vitro and in vivo
MRS. The first applications of HR-MAS MRS on human
tissue specimens date back to 1997 (17,18) and have become
possible thanks to the commercial diffusion of MRS probe-
heads capable of studying the samples in rapid rotation around
an axis 54.7˚ (‘magic angle’) tilted with respect to that of
the static magnetic field. These probe-heads drastically
reduce contributions from dipolar couplings and chemical
shift anisotropy providing high resolution spectra from
semi-solid samples such as tissues (19-26). The quality of the
obtained spectra is comparable to that obtained from aqueous
extracts (in vitro MRS), and the acquisition techniques which
is possible to utilize are the same, with the advantage of
carrying out the measurements on intact tissue specimens,
without any pretreatment.
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The ability of the ex vivo HR-MAS MRS analysis is to
relate the biochemical composition with quantitative histo-
pathologic findings from the same tissues to determine the
metabolic profiles associated with functional, benign and
malignant tissues. Correlations between some metabolites
and proliferative markers to gain insight into the relationships
between cellular proliferation and the metabolic changes
associated with the presence and aggressiveness are thus
possible.
To our knowledge, no studies have been reported in the
international scientific literature dealing with the application
of ex vivo HR-MAS MRS in the characterization of the bio-
chemical composition of human gastrointestinal mucosa.
From this perspective our research group will investigate the
biochemical composition of normal human gastric mucosa
by means of ex vivo HR-MAS MRS. As a part of a more
comprehensive study on the biochemical characterization of
human healthy and neoplastic tissue (5,27-40), the aim of this
study is to characterize the molecular pattern of a healthy
human gastric mucosa for the comparison with gastric adeno-
carcinomatous tissues which will be studied in a near future.
Materials and methods
Clinical materials
Selection of the patients. Five patients were enrolled and
gave written informed consent to participate in the study which
was approved by the local research ethics committee. For
each eligible patient, 6 biopsies were taken (3 biopsies from
the antrum and 3 biopsies from the gastric body) during
endoscopy. Among them, 4 have been used for routine histo-
logic evaluation (hematoxylin-eosin) and 2 were put in liquid
nitrogen and stored at -85˚C. Endoscopy was performed
using Olympus Instruments 140 series and biopsy forceps
Olympus FB24Q, after sterilization in acetylacetic acid. The
biopsies were obtained, on healthy tissues, in the subjects who
do not present visible macroscopic alterations and the tissue
was considered healthy only if the histological examination
confirmed the macroscopic finding.
Tissue samples. The tissue samples were put in liquid nitrogen
and stored at -85˚C until MRS analyses. Before MRS analyses
all samples were flushed with D2O prior to the insertion in
MAS rotor (4 mm OD). Samples and instrument preparation
take about 20 min.
Magnetic resonance spectroscopy. Proton HR-MAS spectra
were recorded with a Bruker Avance400 spectrometer
equipped with a 1H/13C HR-MAS probe, utilizing the sequences
implemented in Bruker software. Samples were spun at 4000
Hz and three different types of 1D (monodimensional) proton
spectra were acquired by using: i) a composite pulse sequence
(zgcppr) (41) with 1.5 sec water-presaturation during relaxation
delay, 8 kHz spectral width, 32 k data points, 32-64 scans; ii)
a water-suppressed spin-echo Carr-Purcell-Meiboom-Gill
sequence (42) (cpmgpr) with 1.5 sec water-presaturation
during relaxation delay, 1 msec echo time (
 
Ù) and 360 msec
total spin-spin relaxation delay (2nÙ), 8 kHz spectral width,
32 k data points, 256 scans; and iii) a sequence for diffusion
measurements based on stimulated echo and bipolar-gradient
pulses (ledbpgp2s1d) (43) with ∆ 200 msec, eddy current delay
Te 5 msec, ‰ 2x2 msec, sine-shaped gradient with 32 G/cm
followed by a 200 µsec delay for gradient recovery, 8 kHz
spectral width, 8 k data points, 256 scans. Two-dimensional
1H,1H-COrrelation SpectroscopY (COSY) (44,45) spectra were
acquired using a standard pulse sequence (cosygpprqf) and
0.5 sec water-presaturation during relaxation delay, 8 kHz
spectral width, 4 k data points, 32 scans per increment, 256
increments. Two-dimensional (2D) 1H,1H-TOtal Correlation
SpectroscopY (TOCSY) (46,47) spectra were acquired using
a standard pulse sequence (mlevphpr) and 1 sec water-
presaturation during relaxation delay, 100 msec mixing
(spin-lock) time, 4 kHz spectral width, 4 k data points, 32
scans per increment, 128 increments. Two-dimensional J-
resolved (J-Res) spectra were acquired using the standard
pulse sequence (lcjresprqf) (48) 1.5 sec water-presaturation
during relaxation delay, 3.6 kHz spectral width in f2, 61 Hz
in f1, 4 k data points, 16 scans per increment and 64 increments.
Two-dimensional 1H,13C-Heteronuclear Single Quantum
Coherence (HSQC) (49) spectra were acquired using an echo-
antiecho phase sensitive standard pulse sequence (hsqcetgp)
and 0.5 sec relaxation delay, 1.725 msec evolution time, 4 kHz
spectral width in f2, 4 k data points, 128 scans per increment,
17 kHz spectral width in f1, 256 increments.
Results and Discussion
The 1D proton spectra obtained from two representative
samples of normal gastric mucosa (1 and 2), acquired at time =
0 by using a presaturation sequence with composite pulse
(Bruker zgcppr), are reported in Fig. 1.
The spectra of these samples, which are representative of
the all that analysed, show the presence of the resonances
deriving from metabolites and macromolecules with short T2,
but not so short to be MRS invisible, and are characterised by
signals with a resolution comparable to that obtained for
solution spectra. Furthermore, it is to note that in stomach
tissues the lipid content is very low in comparison with that
of other metabolites, as can be derived from the low intensity
ratio between signals at 1.3 ppm (CH2)n, and at 0.89 ppm CH3
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Figure 1. HR-MAS proton MR spectra of normal human gastric mucosa
(a, sample 1, and b, sample 2).
(usually around 3:1). In order to evaluate the stability of the
samples in the HR-MAS probe, the spectra were obtained at
different times from their preparation. The spectra of sample
1 obtained after 3 h (trace a) and after 6 h (trace b) from the
preparation are reported in Fig. 2. These spectra evidence a
progressive increase of spectral resolution probably related to
the increasing mobility of some metabolites, as a consequence
of the partial disruption of subcellular structures. In any case,
the lactate content does not appreciably change, whereas
changes related to the mobility enhancement of amino acidic
fractions are detected: an increase of glycine, alanine and
other aliphatic and aromatic amino acids, and free choline is
observed. We are not able to give a straightforward explanation
of this behaviour; however we recall that the progastrin is
cleaved at pairs of basic amino acids by a pro-hormone
converter to form a glycine intermediate (G-Gly) that serves
as a substrate for peptide-glycine ·-amidating mono oxigenase
(50). Since an overexpression of gastrin, known to promote
the growth of several neoplasms, in human gastric carcinomas
has been demonstrated (51), the presence of glycine could
merit further investigations.
In order to separate the contribution of resonances due
to macromolecules having short spin-spin relaxation times,
spectra were acquired using a CPMG spin-echo sequence
[90˚ - (Ù-180˚-Ù)n], choosing Ù and n in order to separate signals
according to their different T2. Signals from macromolecules,
having short T2 (or large linewidth) are attenuated leaving only
the resonances due to mobile small molecules. Diffusion-
edited spectra were also acquired choosing a diffusion delay
(∆) and a gradient-field pulse duration (‰) and strength in
order to observe components with low diffusion rates, deriving
from lipids, glycogen and small proteins. A conventional pre-
saturated 1D spectrum with composite pulse (trace a), that
highlights both lipids and small metabolites contribution, a
CPMG spectrum (trace b), showing the enhanced resonances
of metabolites, and the diffusion-edited spectrum (trace c) of
the same stomach sample 3 are reported in Fig. 3.
Although some metabolites can be readily assigned by
direct inspection of the 1H MR spectra (by comparison
with literature data), a complete assignment requires the
acquisition of selected 2D experiments such as COSY
(proton-proton COrrelation SpectroscopY) (44,45,52), TOCSY
(TOtal Correlation SpectroscopY) (46,47), J-Res (J-resolved
experiment) (48) and HSQC (1H,13C-Heteronuclear Single
Quantum Coherence) (49).The COSY and the TOCSY spectra
are very informative for the identification of hidden resonances:
the COSY spectra enable the coupled proton-proton pairs to
be found, whereas the TOCSY spectra permit to identify
1H-1H connectivities up to five or six bonds. The J-Res
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Figure 2. HR-MAS proton MR spectra of sample 1: (a), after 3 h and (b), after
6 h.
Figure 3. 1D proton MR spectra of sample 3: (a), conventional 1H MR
spectrum obtained with water-presaturation and composite pulse, (b) CPMG
spectrum obtained with 360 msec total spin-echo time and (c) diffusion-
edited spectrum obtained with ∆=200 msec, ‰=4 msec and gradient strength
of 32 G/cm.
Figure 4. Partial COSY MR spectrum of sample 4. The identified metabolites
are denoted with labels according to Table I.
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Table I. List of 1H and 13C chemical shift (‰, ppm) of meta-
bolites found in HR-MAS spectra of human healthy stomach
tissue.a,b
–––––––––––––––––––––––––––––––––––––––––––––––––
Entry Metabolite ‰ 1H ‰ 13C
–––––––––––––––––––––––––––––––––––––––––––––––––
1 Fatty acids 0.89 14.6 CH3
1.31 (CH2)n
1.62 CH2-C-C=O
2.02 CH2-C=
2.29 34.2 CH2C=O
2.78 =C-CH2-C=
5.32 CH=CH
2 Isoleucine 0.94(t) 11.7 ‰-CH3
1.02(d) 15.5 Á-CH3
1.29, 1.48 25.1 Á-CH2
1.97 ß-CH
3.69 ·-CH
3 Leucine 0.95(d) 21.6 ‰-CH3
0.97(d) 22.7 ‰-CH3
1.70 24.8 Á-CH
1.72 40.5 ß-CH2
3.75 c ·-CH
4 Valine 0.99(d) 17.3 Á-CH3
1.04(d) 18.7 Á-CH3
2.25 ß-CH
3.61 d ·-CH
5 Threonine 1.33(d) 20.3 Á-CH3
4.27 ß-CH
3.60 d ·-CH
6 Lactate 1.33(d) 20.3 CH3
4.11 CH
7 Unknown 1.37(t) CH3
3.36(q) CH2
8 Alanine 1.48(d) 16.8 ß-CH3
3.79 51.3 ·-CH
9 Lysine 3.04(t) 39.9 Â-CH2
1.73 27.3 ‰-CH2
1.48 22.3 Á-CH2
1.91 30.6 ß-CH2
3.79 c ·-CH
10 Arginine 3.23 41.3 ‰-CH2
1.69 24.9 Á-CH2
1.93 28.3 ß-CH2
3.78 c ·-CH
11 Glutamate 2.36(t) 34.3 Á-CH2
2.06, 2.15 27.6 ß-CH2
3.77 c ·-CH
12 Glutamine 2.48(td) 31.7 Á-CH2
2.14 27.1 ß-CH2
3.79 c ·-CH
13 Proline 3.43, 3.34 ‰-CH2
2.01 Á-CH2
2.34, 2.07 ß-CH2
4.12 ·-CH
14 Methionine 2.13(s) 14.9 SCH3
2.70 Á-CH2
2.25 ß-CH2
3.87 ·-CH
15 Aspartatic acid 2.68, 2.82 37.5 ß-CH2
3.90 ·-CH
16 Asparagine 2.85, 2.96 ß-CH2
4.01 ·-CH
17 Creatine 3.04(s) NCH3
3.92(s) CH2
18 Tyrosine 3.06, 3.20 ß-CH2
3.93 57.0 ·-CH
6.88 116.8 Hortho
7.20 131.7 Hmeta
Table I. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––
Entry Metabolite ‰ 1H ‰ 13C
–––––––––––––––––––––––––––––––––––––––––––––––––
19 Phenylalanine 3.11, 3.28 ß-CH2
3.98 ·-CH
7.33 130.1 Hortho
7.37 Hpara
7.43 129.6 Hmeta
20 Ethanolamine 3.15(t) CH2
3.82(t) CH2
21 Phosphoryl- 3.23 41.1 CH2
ethanolamine 4.00 61.1 CH2
22 Glycerophospho- 3.30 CH2
rylethanolamine 4.12 CH2
23 Free Choline 3.20 54.6 N(CH3)3
3.53 68.2 NCH2
4.07 56.5 OCH2
24 Glycerophos- 3.22 54.7 N(CH3)3
phorylcholine 3.68 NCH2
4.33 OCH2
25 Phosphoryl- 3.22 54.7 N(CH3)3
choline 3.61 67.3 NCH2
4.21 59.0 OCH2
26 ß-glucose 3.25 2-CH
4.67(d) 1-CH
27 Taurine 3.26(t) 48.2 SCH2
3.42(t) 36.2 NCH2
28 Myoinositol 3.29(t) 75.3 5-CH
3.63(t) 73.2 4,6-CH
3.53(dd) 72.0 1,3-CH
4.06(t) 72.9 2-CH
29 Scyllo-inositol 3.35 (s)
30 ·-glucose 3.54 2-CH
5.24(d) 1-CH
31 Glycine 3.56 42.3 CH2
32 PEG 3.72 70.3
33 Glycerol 4.10, 4.30 1,3-CH2
(in lipids) 5.26 2-CH
34 Glycerols 3.57, 3.66 63.2 1-CH2
3.81 72.7 2-CH
35 UDPG 4.34 2-CHrib
5.92 1-CHrib
5.90 5-CHur
7.87 6-CHur
36 Uracil 5.80 5-CHur
7.53 6-CHur
37 Formiate 8.48
38 NADH 8.21
39 Tryptophane 7.73 4-CH
7.19 5-CH
7.29 6-CH
7.52 7-CH
40 Adenine 8.18 8-CH
8.21 2-CH
41 NAc 2.01÷2.12 23.0 NC=OCH3
42 Acetate 1.92 24.8 CH3C=O
43 Unknown 7.97
44 Unknown 7.23÷7.15e
8.23÷8.02e
–––––––––––––––––––––––––––––––––––––––––––––––––
a1H chemical shift are referred to alanine doublet at 1.48 ppm. b13C
chemical shift are referred to alanine at 16.8 ppm. cC· probably
contributes to the 3.77, 55.1 ppm cross-peak. dC· probably
contributes to the 3.61, 61.1 ppm cross-peak. eMobile pair of
singlets.
–––––––––––––––––––––––––––––––––––––––––––––––––
experiments allow us to disentangle overlapped signals and
to distinguish their multiplicity. 1H,13C HSQC spectra were
performed in order to identify directly bonded carbon-proton
correlations that make possible to assign the singlets (which
do not give correlations in homonuclear COSY and TOCSY
spectra) by comparison of both 1H and 13C data with those of
literature, and to distinguish signals from different molecules
having similar proton chemical shifts but diverse 13C signals.
The whole of these experiments permits the complete and
unambiguous identification of the metabolic pattern typical
of the normal human gastric mucosa.
The analysis of the COSY spectrum (Fig. 4) evidences
the presence of a pool of metabolites, especially osmolites,
free amino acids and a fraction of mobile lipids, whose
assignments are reported in Table I.
Some correlations, for example those due to glycerol (in
lipids) protons at 5.24, 4.30 and 4.10 ppm are present in COSY
spectra, but absent or attenuated in TOCSY spectra (Fig. 5).
This difference can be explained by considering that in TOCSY
spectra signals coming from large molecules relax during the
mixing time and this, together with the characteristic chemical
shifts, allows us to say that this glycerol moiety is not involved
in small but belongs to larger lipidic species. The COSY spectra
are particularly useful for the detection and assignment of ·-
hydrogens of several amino acids, whereas the presence of
lysine and arginine is better evidenced in TOCSY spectra.
Both COSY and TOCSY experiments permit to establish that
two metabolites, lactate and threonine, contribute to the doublet
at 1.33 ppm found in 1H MR spectra.
A further insight into the assignment of metabolite signals
can be gained exploiting 13C chemical shift dispersion in the
second dimension, with an HSQC experiment. The HSQC
spectrum of sample 5 and relative assignments are reported
in Fig. 6. Choline containing compounds, arginine and phos-
phorylethanolamine (PE) contribute all to the 3.2 ppm signal
in the proton spectra but can be readily distinguished with
HSQC due to the large difference in 13C chemical shifts. The
13C ‰ dispersion is also useful for the assignment of the signals
of aliphatic amino acids (isoleucine, valine, leucine). The
interpretation of the region between 3.4 and 4.0 ppm is more
problematic, due to the presence of overlapped correlations
around 62 ppm, presumably due to glycerols. All sample
spectra show a strong resonance at 3.72 (s) ppm, attributable
to the polyethylene glycol (PEG) used as an excipient in
pharmaceuticals (confirmed by the 13C resonance at 70.3 ppm).
The observed peaks seem to be principally related to the
narrow components appearing in the CPMG spectrum (Fig. 3b),
with the exception of signals due to N-acetyl groups (probably
arising from sialic acid), which are instead evidenced in the
diffusion-edited spectrum (Fig. 3c).
We were able through the use of suitable one- and two-
dimensional experiments to assign the MRS signals from more
than forty species present in healthy human gastric mucosa.
Among them only few components can to be confidently
assigned by direct inspection of the 1H MR spectrum, namely,
a doublet at 1.48 ppm is for alanine, a triplet at 2.36 ppm is
for glutamic acid, whereas a triplet at 3.43 ppm is for taurine.
Instead, the doublet at 1.33 ppm, usually attributed to lactate, is
due in our samples to the overlapping of lactate and threonine
resonances, with the second species prevailing in the same
cases. The presence of lysine is normally well evident in the
one-dimensional 1H spectrum from the triplet at 3.04 ppm
(over-lapped to the singlet of creatine), while it is harder to
distinguish the triplet of arginine from those of taurine and
phosphorylethanolamine which are found very close in one-
dimensional 1H spectrum (and partially hidden under the
choline containing compounds singlets).
In conclusion, this report represents the first study, to our
knowledge, aimed at elucidating the metabolic profile of
normal human gastric mucosa by ex vivo HR-MAS MRS. All
the samples analysed display the same resonances with only
slight differences in the relative abundance. The 1D and 2D
MRS techniques allow for the identification of several
species. We have characterized the molecular pattern typical
of the healthy gastric human mucosa: these biochemical data
will be at the bases of the comparison with gastric neoplastic
situations. Moreover, the full knowledge of the biochemical
pattern of the healthy gastric tissues is the necessary pre-
supposition for the application of magnetic resonance spectro-
scopy directly on the patient.
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Figure 5. Partial TOCSY MR spectrum of sample 4. The identified metabolites
are denoted with labels according to Table I.
Figure 6. Partial 1H,13C-HSQC spectrum of sample 5. The identified meta-
bolites are denoted with labels according to Table I.
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